Romiplostim, low‐dose rituximab and high‐dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study
Therapies such as corticosteroids, thrombopoietin receptor agonists and immunomodulators have been consistently under the spotlight in the search for a better treatment for immune thrombocytopenia (ITP). However, none of them has been widely embraced as a new standard. In this pilot study, we investigated feasibility, safety and preliminary efficacy of romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed ITP. We conducted a single-centre single-arm pilot. One-month treatment adherence was 100%. The 1-month overall response rate was 92.3%. Complete response occurred in 11 (84.6%) patients. Median duration of response was 4.13 monts (range 0.2-25). No serious adverse events presented.
Authors
- David Gómez‐Almaguer (ORCID: https://orcid.org/0000-0002-0460-6427)
- Olga Graciela Cantú‐Rodríguez (ORCID: https://orcid.org/0000-0003-2134-3734)
- Andrés Gómez‐De León (ORCID: https://orcid.org/0000-0001-6904-9345)
- Mónica Bustillos‐Muñoz
- Héctor Alejandro Vaquera Alfaro (ORCID: https://orcid.org/0000-0001-9657-9130)
- Perla R. Colunga‐Pedraza (ORCID: https://orcid.org/0000-0002-9937-439X)
- Luz Tarín‐Arzaga (ORCID: https://orcid.org/0000-0003-2512-570X)
- Fernando De la Garza‐Salazar (ORCID: https://orcid.org/0000-0003-0080-487X)
- Cesar Homero Gutiérrez‐Aguirre (ORCID: https://orcid.org/0000-0002-9876-3633)
Institutions
- Universidad Autónoma de Nuevo León (MX)
- Hospital Universitario Dr José Eleuterio Gonzalez (MX)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1111/bjh.19923
- Citations
- 2
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91